Swing Trader Downtrend Protection v.2 - Generating 7.47% for ZOM
Capitalizing on the Swing: How Downtrend Protection v.2 (TA) Delivered 7.47% Returns for ZOM Amidst Pharmaceuticals' Varied Market Cap
In a dynamic space, the pharmaceutical industry is teeming with companies of varied sizes, capabilities, and financial magnitudes. The average market capitalization across the Pharmaceuticals sector stands at a formidable $2.3 billion, reflecting the robust financial backing of most entities in this area. However, the spread within the group is notably vast, ranging from a modest $246 million to a whopping $77.8 billion.
The pharmaceutical giant Zoetis Inc. (ZTS) stands at the pinnacle of this range, boasting the highest market capitalization at $77.8 billion. The smallest market cap within this group belongs to PEMTF, with a comparatively meager valuation of $246 million.
However, amidst this variegated financial landscape, Zomedica Corp. (ZOM) has carved out a niche for itself. The company recently experienced a notable surge in its returns, thanks to the strategic implementation of the Downtrend Protection v.2 (TA) trading technique, better known as the Swing trading method.
For the uninitiated, Swing trading involves taking advantage of the natural oscillation of stock prices, capitalizing on the upswing, and protecting capital during downturns. This approach offers opportunities for higher returns and risk management, especially in volatile markets.
Zomedica, by adopting the Downtrend Protection v.2 (TA), managed to generate a commendable 7.47% return, a testament to the efficacy of this trading approach. This strategy, designed to shield investments during periods of market volatility, appears to have worked in favor of ZOM.
The use of this technical analysis tool showcases ZOM's ability to strategize its moves amidst a volatile and diverse market environment, thereby optimizing returns for its investors. It is worth noting that the swing trading strategy employed is not about getting the highest possible peak, but about gaining consistent returns. This underlines ZOM's prudent investment approach.
In conclusion, Zomedica's case demonstrates that market capitalization, while important, is not the sole determinant of success in the pharmaceutical industry. Strategic trading mechanisms like Downtrend Protection v.2 (TA) can help companies optimize their returns, even in the face of volatile market conditions and varied capitalizations.
ZOMDF in upward trend: price expected to rise as it breaks its lower Bollinger Band on March 03, 2026
ZOMDF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 39 cases where ZOMDF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
ZOMDF moved above its 50-day moving average on March 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZOMDF advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 40 cases where ZOMDF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on February 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZOMDF as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ZOMDF turned negative on February 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for ZOMDF crossed bearishly below the 50-day moving average on March 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZOMDF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ZOMDF entered a downward trend on March 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.080) is normal, around the industry mean (14.142). P/E Ratio (0.000) is within average values for comparable stocks, (41.117). ZOMDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.600). ZOMDF's Dividend Yield (0.000) is considerably lower than the industry average of (0.020). P/S Ratio (4.388) is also within normal values, averaging (34.951).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZOMDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZOMDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that develops medication for animals
Industry MedicalNursingServices
Advertisement